Trulieve Cannabis Corp. (TRLV) is a prominent player in the US cannabis market, distinguished by its comprehensive vertical integration that encompasses cultivation, production, and retail distribution of cannabis products. With a significant presence in critical states like Florida, Trulieve is dedicated to delivering high-quality and innovative solutions that cater to a diverse consumer base. The company’s robust commitment to community involvement and sustainable business practices not only enhances its brand reputation but also positions Trulieve strategically for long-term growth amidst the dynamic landscape of the cannabis industry.
| Revenue (TTM) | $1.14B |
| Gross Profit (TTM) | $677.39M |
| EBITDA | $301.02M |
| Operating Margin | 12.80% |
| Return on Equity | -47.60% |
| Return on Assets | 3.28% |
| Revenue/Share (TTM) | $5.93 |
| Book Value | $3.99 |
| Price-to-Book | 3.13 |
| Price-to-Sales (TTM) | 1.69 |
| EV/Revenue | 2.329 |
| EV/EBITDA | 6.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -10.30% |
| Shares Outstanding | $170.16M |
| Float | $167.89M |
| % Insiders | 1.23% |
| % Institutions | 24.28% |
Volatility is currently contracting
Here, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.
TALLAHASSEE, Fla., Oct. 7, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced the full repayment of an approximately $65 million mortgage notes payable secured by a cultivation site in Jefferson County, Florida, thereby reducing outstanding debt to approximately $225 million.
TALLAHASSEE, Fla., Oct. 6, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV ) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., will hold a conference call on Thursday, November 5, 2026 at 8:30 AM Eastern Time following the release of its third quarter 2026 financial results.
I reiterate my Buy rating on AdvisorShares Pure US Cannabis ETF despite the DEA pausing rescheduling hearings. MSOS remains attractive as the rescheduling catalyst is delayed, not canceled, and underlying holdings appear reasonably valued. Trulieve Cannabis Corp., MSOS's largest holding, stands out due to its Florida medical sales focus and normalized tax rates.
The marijuana industry is entering another important period for investors as September 2026 gets underway. Cannabis stocks have experienced significant volatility over the past several years. However, several major operators continue building their businesses despite challenging industry conditions.
Perpetual Royalty-Free License Covers Alien Labs and Connected Brands TALLAHASSEE, Fla., Sept. 28, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S, today announced a licensing deal with Connected for the exclusive rights to genetics, trademarks, and proprietary know-how to produce and sell Alien Labs and Connected branded cannabis products in Florida and Texas.
Cannabis stocks are entering a potentially transformative period as federal reform takes hold. Stronger business fundamentals and wider market access are reshaping the legal cannabis industry. For cannabis investors and enthusiasts, this moment represents more than short-term stock-market excitement—it reflects the gradual evolution of cannabis from a restricted market into a more established American industry.
Inclusion Marks Another Milestone as Trulieve Broadens U.S. Capital Markets Exposure TALLAHASSEE, Fla., Sept. 22, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that the company has been added to the S&P Total Market Index (TMI), S&P Completion Index (CI), and sector sub-indices S&P TMI Health Care and S&P CI Health Care.
Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal.
New DeKalb County location will host grand opening celebration Thursday, September 10 TALLAHASSEE, Fla., Sept. 4, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Dunwoody, Georgia.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TRLV and any ticker you trade — then tracks every position and per-strategy win rate.
